Genentech, Roche, divarasib, KRAS G12C, non-small cell lung cancer, NSCLC, Krascendo 1, Phase 3 clinical trial, targeted therapy, oncology, lung cancer research, overall survival

South San Francisco, California, U.S., October 25, 2026 Genentech, a member of the Roche Group, announced positive Phase 3...